> Becton, Dickinson is buying GeneOhm Sciences for $230 million and $25 million in incentive payments. GeneOhm makes infection tests. Article
> Celera Genomics has acquired full control of its Celera Diagnostics joint venture, acquiring Applied Biosystems' 50 percent interest. Celera paid $30 million in cash to complete the restructuring. Release
> The FDA has approved ZLB Behring's Vivagloben, providing patients with a rare primary immunodeficiency a way to self-administer immune globulin. Article
> The FDA has approved LEO Pharma's Taclonex for psoriasis. Release
> Teva's takeover of IVAX has been delayed from closing on schedule. Article
> MorphoSys and Chemicon International have inked a licensing deal for research antibodies. Release
> Cephalon and Mylan have settled their patent dispute over Provigil. Article
> Affymetrix and Duke University have struck a five-year collaboration deal in which Duke researchers will use Affymetrix's GeneChip microarray technology to look for RNA and DNA patterns that can be used to classify and treat cardiovascular and cancer disease. Release
> Amylin Pharmaceuticals is preparing a long-term trial for an extended release version of its diabetes drug Byetta. Report
> Human Genome Sciences has inked a licensing deal with Amgen for a gene that may play a role in autoimmune diseases, immune deficiencies or suppression, and cancer. Release
> Caprion Pharmaceuticals has struck an oncology target licensing deal with ImClone. Release
> Chutes & Ladders: The top sales executive at MedImmune has been let go without explanation. Article
> Chutes & Ladders: Richard Lotti has joined Aperon Biosystems as CEO. Release
And Finally... The Los Angeles Times takes an in-depth look at bird flu and its prospects for jumping the Bering Strait into the U.S. Article